Skip to main content
Clinical Trials/NCT03494088
NCT03494088
Unknown
N/A

Mycobiome Evaluation in Children With Autism & GI Symptoms

The University of Texas Health Science Center, Houston1 site in 1 country60 target enrollmentMarch 22, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Autism
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
60
Locations
1
Primary Endpoint
Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species
Last Updated
7 years ago

Overview

Brief Summary

This study's primary aim is to explore the potential differences in the gut mycobiome of children with autism spectrum disorder compared to otherwise healthy children. The secondary objective of this study is to evaluate whether the presence of specific species of fungi (e.g. Candida tropicalis, C. albicans, or Saccharomyces cerevisiae), in stool: 1) correlates with increased gastrointestinal symptoms; 2) correlates with evidence of increased behavioral problems (as assessed by the Aberrant Behavior Checklist or Social Responsiveness Scale-2); or 3) plays the same role as a constituent of commensal gut microflora as in normal controls. The scale indicates severity of social deficits in the autism spectrum as mild, moderate or severe. Additionally, the study aims to compare the fecal and oral fungi in these children because many fecal mycobiota are felt to originate in the oropharynx.

Registry
clinicaltrials.gov
Start Date
March 22, 2018
End Date
May 1, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jane J Alookaran

Pediatric gastroenterology fellow

The University of Texas Health Science Center, Houston

Eligibility Criteria

Inclusion Criteria

  • for autistic children with GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (DSM-5: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2); substantial gastrointestinal symptoms (as indicated by score of greater than 7 on the Gastrointestinal Symptoms Severity Index)
  • for autistic children without GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (DSM-5: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2)
  • for controls: healthy children

Exclusion Criteria

  • severe sensory impairment
  • brain injury
  • major psychiatric illness (e.g., psychotic disorders that might interfere with assessment). (however, children with common psychological problems such as depression and attention deficit hyperactivity disorder will not be excluded, given that doing so would result in a sample of children with ASD that would be unrepresentative of the pediatric ASD population as a whole.)- children who appear genetically syndromic (based on exam in the pediatric GI clinic)
  • taking immunosuppressive medications
  • abnormal screening labs
  • GI diseases
  • allergy to antibiotics
  • fever or a pre-existing adverse event monitored in the study
  • known history of hepatitis B/C or HIV
  • known pregnancy

Outcomes

Primary Outcomes

Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species

Time Frame: day 1

Secondary Outcomes

  • Oral Mycobiome Composition as assessed by sequencing of oral fungal species(day 1)
  • Presence of fungal species Saccharomyces cerevisiae(day 1)
  • Antifungal immunity as assessed by serum dectin 1 levels(day 1)
  • Presence of fungal species Candida tropicalis(day 1)
  • Gastrointentinal (GI) symptoms as assessed by the GI Symptoms Severity Index(day 1)
  • Gut inflammation as assessed by fecal calprotectin levels(day 1)
  • Presence of fungal species Candida albicans(day 1)
  • Behavioral problems as assessed by the Aberrant Behavior Checklist (ABC)(day 1)
  • Behavioral problems as assessed by the Social Responsiveness Scale-2 (SRS-2)(day 1)

Study Sites (1)

Loading locations...

Similar Trials